FDA issued a warning letter to a compounder citing violations based on making copies of FDA-approved GLP-1 drugs. The warning letter to Empower Pharmacy also cites sterility concerns because their drugs were made in a facility where FDA observed insanitary conditions.

FDA is committed to protecting patients from poor quality compounded GLP-1 drugs and will continue taking action when companies fail to follow federal law. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026